Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
- Conditions
- Acromegaly
- Registration Number
- NCT06344650
- Lead Sponsor
- IRCCS San Raffaele
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria:<br><br> - confirmed diagnosis of acromegaly<br><br> - availability to carry out outpatient checks<br><br> - ability to provide informed consent<br><br>Exclusion Criteria:<br><br> - Pregnancy<br><br> - use of glucocorticoids (except those in use for replacement therapy)<br><br> - alcohol abuse<br><br> - exacerbation of chronic disease<br><br> - serious comorbidities (renal or hepatic failure, heart attack, stroke)<br><br> - terminally ill, prolonged immobilization (>1 week)<br><br> - clinically evident fracture within the previous six months<br><br> - any other cause of secondary osteoporosis within the last five years<br><br> - any prolonged treatment with drugs with documented influence on bone metabolism<br> during the previous 12 months, including treatment with antiresorptive or anabolic<br> compounds for osteoporosis.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identify the rate of morphometric vertebral fractures in acromegalic patients
- Secondary Outcome Measures
Name Time Method